In This Issue

385  In This Issue of Diabetes Care

Editorial

387  American Diabetes Association’s Standards of Care: A Paradigm Shift in the Dissemination of Information
W.T. Cefalu, E.G. Berg, M.P. Petersen, and T. Darsow

Commentary

389  Are All Patients With Type 1 Diabetes Destined for Dialysis If They Live Long Enough? Probably Not
G.L. Bakris and M. Molitch

ADA Award Lecture

391  Assessing Health-Related Quality of Life in Patients With Diabetic Foot Disease: Why Is It Important and How Can We Improve? The 2017 Roger E. Pecoraro Award Lecture
D.K. Wukich and K.M. Raspovic

Clinical Care/Education/Nutrition/PsychoSocial Research

398  Targeted Microbiome Intervention by Microencapsulated Delayed-Release Niacin Beneficially Affects Insulin Sensitivity in Humans

406  Prospective, Cluster-Randomized Trial to Implement the Ottawa Model for Smoking Cessation in Diabetes Education Programs in Ontario, Canada

413  Changes in Gut Microbiota–Related Metabolites and Long-term Successful Weight Loss in Response to Weight-Loss Diets: The POUNDS Lost Trial
Y. Heianza, D. Sun, S.R. Smith, G.A. Bray, F.M. Sacks, and L. Qi

Epidemiology/Health Services Research

420  Low Incidence of End-Stage Renal Disease in Childhood-Onset Type 1 Diabetes Followed for Up to 42 Years

426  Cumulative Kidney Complication Risk by 50 Years of Type 1 Diabetes: The Effects of Sex, Age, and Calendar Year at Onset
T. Costacou and T.J. Orchard

434  Incidence of End-Stage Renal Disease in Patients With Type 1 Diabetes
J. Helve, R. Sund, M. Aafmann, V. Harjutsalo, P.-H. Groop, C. Grönhagen-Riska, and P. Finne

440  Plasma Alkylresorcinol Metabolite, a Biomarker of Whole-Grain Wheat and Rye Intake, and Risk of Type 2 Diabetes and Impaired Glucose Regulation in a Chinese Population

446  The Bidirectional Association Between Depression and Severe Hypoglycemic and Hyperglycemic Events in Type 1 Diabetes
P. Gilsanz, A.J. Karter, M.S. Beeri, C.P. Quesenberry Jr., and R.A. Whitmer

453  Effect of Changing Work Stressors and Coping Resources on the Risk of Type 2 Diabetes: The OHSPIW Cohort Study
Y. Lian, Q. Sun, S. Guan, H. Ge, N. Tao, Y. Jiang, Y. Zhang, L. Ning, J. Xiao, and J. Liu

461  Associations of Four Community Factors With Longitudinal Change in Hemoglobin A1c Levels in Patients With Type 2 Diabetes

469  Diabetes Is Associated With Reduced Stress Hyperlactatemia in Cardiac Surgery

478  Markedly Decreasing Incidence of Blindness in People With and Without Diabetes in Southern Germany
H. Claessen, T. Kvitkina, M. Narres, C. Trautner, I. Zöllner, B. Bertram, and A. Icks

485  BMI and Mortality in Patients With New-Onset Type 2 Diabetes: A Comparison With Age- and Sex-Matched Control Subjects From the General Population

494  Associations of General and Central Adiposity With Incident Diabetes in Chinese Men and Women

503  Risk of Hypoglycemia Following Hospital Discharge in Patients With Diabetes and Acute Kidney Injury

513  Risk of Infection in Type 1 and Type 2 Diabetes Compared With the General Population: A Matched Cohort Study
I.M. Carey, J.A. Critchley, S. DeWilde, T. Harris, F.J. Hosking, and D.G. Cook

522  Early Infant Diet and Islet Autoimmunity in the TEDDY Study

Emerging Technologies and Therapeutics

531  Pharmacokinetic and Pharmacodynamic Characteristics of Dasiglucagon, a Novel Soluble and Stable Glucagon Analog

538  Effects of Pemafibrate, a Novel Selective PPARα Modulator, on Lipid and Glucose Metabolism in Patients With Type 2 Diabetes and Hypertriglyceridemia: A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial

547  Metformin Treatment in Patients With Type 2 Diabetes and Chronic Kidney Disease Stages 3A, 3B, or 4
J.-D. Lalau, F. Kojab, Y. Bennis, A.-S. Hurtle-Lemaire, F. Belaire, and M.E. De Broe
Pathophysiology/Complications

554  TCF7L2 Genetic Variation Augments Incretin Resistance and Influences Response to a Sulfonylurea and Metformin: The Study to Understand the Genetics of the Acute Response to Metformin and Glipizide in Humans (SUGAR-MGH)

Cardiovascular and Metabolic Risk

562  Objectively Measured Physical Activity and Sedentary Time Are Associated With Cardiometabolic Risk Factors in Adults With Prediabetes: The PREVIEW Study

570  Advanced Glycation End Products, Oxidation Products, and Incident Cardiovascular Events in Patients With Type 2 Diabetes
J. Koska, A. Sarem, S. Howell, G. Bahn, B. De Courten, H. Ginsberg, P.J. Beisswenger, and P.D. Reaven, for the VADT Investigators

577  Risk Assessment in Patients With Diabetes With the TIMI Risk Score for Atherothrombotic Disease

586  Validation of Risk Equations for Complications of Type 2 Diabetes (RECODE) Using Individual Participant Data From Diverse Longitudinal Cohorts in the U.S.

596  Increased Risk of Severe Hypoglycemic Events Before and After Cardiovascular Outcomes in TECOS Suggests an At-Risk Type 2 Diabetes Frail Patient Phenotype

604  Characteristics Associated With Decreased or Increased Mortality Risk From Glycemic Therapy Among Patients With Type 2 Diabetes and High Cardiovascular Risk: Machine Learning Analysis of the ACCORD Trial
S. Basu, S. Raghavan, D.J. Wexler, and S.A. Berkowitz

613  Clinical Impact of ITCA 650, a Novel Drug-Device GLP-1 Receptor Agonist, in Uncontrolled Type 2 Diabetes and Very High Baseline HbA1c: The FREEDOM-1 HBL (High Baseline) Study
R.R. Henry, J. Rosenstock, D.S. Denham, P. Prabhakar, L. Kjems, and M.A. Baron

Novel Communications in Diabetes

620  No Evidence of Increase in Calcitonin Concentrations or Development of C-Cell Malignancy in Response to Liraglutide for Up to 5 Years in the LEADER Trial
L. Hegedus, S.I. Sherman, R.M. Tuttle, B.J. von Scholten, S. Rasmussen, J.D. Karshøj, and G.H. Daniels, for the LEADER Publication Committee on behalf of the LEADER Trial Investigators

623  Fasting Glucose and All-Cause Mortality by Age in Diabetes: A Prospective Cohort Study
S.-W. Yi, S. Park, Y.-h. Lee, B. Barkou, and J.-J. Yi

Review

627  Gastrointestinal Symptoms in Diabetes: Prevalence, Assessment, Pathogenesis, and Management

Clinical Images in Diabetes

638  Anti–Programmed Death 1 (PD-1) Antibodies and the Pancreas: A Diabetic Storm Ahead?
L. Marchand, A. Thivolet, P. Saintigny, N. Fabien, J. Vuillarmet, and C. Thivolet

Errata

640  Erratum. Factors Associated With Diabetes-Specific Health-Related Quality of Life in Youth With Type 1 Diabetes: The Global TEENs Study. Diabetes Care 2017;40:1002–1009

640  Erratum. Mitigating Cardiovascular Risk in Type 2 Diabetes With Antidiabetes Drugs: A Review of Principal Cardiovascular Outcome Results of EMPA-REG OUTCOME, LEADER, and SUSTAIN-6 Trials. Diabetes Care 2017;40:821–831
S. Kaul


Issues and Events

642  Issues and Events

e-Letters – Observations

621  Effect of Single Dose of RANKL Antibody Treatment on Acute Charcot Neuro-osteoarthropathy of the Foot

623  Immunoabsorption Followed by Rituximab as a Definitive Treatment for Insulin Autoimmune Syndrome (Hirata Syndrome): A Case Report

625  Six-Year Diabetes Incidence After Genetic Risk Testing and Counseling: A Randomized Clinical Trial
J.L. Vassy, W. He, J.C. Florez, J.B. Meigs, and R.W. Grant

e-Letters – Comments and Responses

T. Wu, C.S. Marathe, M. Horowitz, K.L. Jones, and C.K. Rayner

B.W. Bode, K. Bowering, and D. Russell-Jones
F.J. Snoek, N. Hermanns, M. de Wit, J. Huber, J. Sturt, F. Pouwer, C.E. Lloyd, I. Willaing, and A. Nouwen, on behalf of the Psychosocial Aspects of Diabetes Study Group of the European Association for the Study of Diabetes


Comment on Jaiswal et al. Prevalence of and Risk Factors for Diabetic Peripheral Neuropathy in Youth With Type 1 and Type 2 Diabetes: SEARCH for Diabetes in Youth Study. Diabetes Care 2017;40:1226–1232
A. Simoneau, M. Monlun, P. Poupon, L. Baillet-Blanco, L. Alexandre, K. Mohammedi, and V. Rigalleau

Response to Comment on Jaiswal et al. Prevalence of and Risk Factors for Diabetic Peripheral Neuropathy in Youth With Type 1 and Type 2 Diabetes: SEARCH for Diabetes in Youth Study. Diabetes Care 2017;40:1226–1232
M. Jaiswal, J. Divers, R. Pop-Busui, and E.L. Feldman

Comment on Ohkuma et al. Cardiac Stress and Inflammatory Markers as Predictors of Heart Failure in Patients With Type 2 Diabetes: The ADVANCE Trial. Diabetes Care 2017;40:1203–1209
T. Kawada

Response to Comment on Ohkuma et al. Cardiac Stress and Inflammatory Markers as Predictors of Heart Failure in Patients With Type 2 Diabetes: The ADVANCE Trial. Diabetes Care 2017;40:1203–1209
T. Ohkuma, M. Woodward, and J. Chalmers, on behalf of the ADVANCE Collaborative Group

The American Diabetes Association (ADA) is the nation’s leading voluntary health organization supporting diabetes research, information, and advocacy. Its mission is to prevent and cure diabetes and to improve the lives of all people affected by diabetes. ADA is the leading publisher of comprehensive diabetes information. Its huge library of books and periodicals covers every aspect of diabetes and diabetes care.

To join ADA: Call 1-800-806-7801 or visit professional.diabetes.org/membership
To subscribe to ADA journals: Call 1-800-DIABETES or go to diabetesjournals.org
To order ADA books: Call 1-800-232-6733 or visit shopdiabetes.org
To access ADA’s library of professional resources: Go to professional.diabetes.org

For more information about diabetes or ADA programs and services: Call 1-800-DIABETES. E-mail: AskADA@diabetes.org or visit diabetes.org

To locate an ADA/NCQA Recognized Provider of quality diabetes care in your area: Visit recognition.ncqa.org

To join the fight to increase funding for diabetes research, end discrimination, and improve insurance coverage: Call 1-800-DIABETES or visit diabetes.org/advocacy

To find out how you can get involved with the programs in your community: Call 1-800-DIABETES or visit diabetes.org/in-my-community

To find out about important research regarding diabetes: Go to diabetes.org/research-and-practice

To make a donation or memorial contribution: Call 1-800-DIABETES or visit diabetes.org/donate